Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

This study is currently recruiting participants.
Verified December 2012 by AHS Cancer Control Alberta
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01428739
First received: October 21, 2010
Last updated: December 10, 2012
Last verified: December 2012
  Purpose

Correlation between MRS and Tumor Response Therapy in Breast Cancer.


Condition Intervention
Breast Cancer
Device: MRS

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • MRS Correlation with Treatment Response [ Time Frame: Up to One Year ] [ Designated as safety issue: Yes ]
    measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment


Secondary Outcome Measures:
  • Correlation with Tumor Stage [ Time Frame: Up to One year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 10
Study Start Date: December 2007
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: MRS
    Procedure
    Other Name: Philips 3 Tesla MRI Scanner
Detailed Description:

Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01428739

Contacts
Contact: Nadeem Pervez, MBBS, FFRRCSI, FRCPC 780-432-8517 nadeem.pervez@albertahealthservices.ca

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Nadeem Pervez, MBBS, FFRRCSI, FRCPC    780-432-8517    nadeem.pervez@albertahealthservices.ca   
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Principal Investigator: Nadeem Pervez, MBBS, FFRRCSI, FRCPC Cross Cancer Institute
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT01428739     History of Changes
Other Study ID Numbers: 23701
Study First Received: October 21, 2010
Last Updated: December 10, 2012
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
cancer
MRS
Treatment response

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on April 17, 2014